153 related articles for article (PubMed ID: 12707729)
21. [Erythropoietin treatment of anemia associated with multiple myeloma (MM) and myelodysplastic syndrome (MDS)].
Qiao ZH
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):122-4. PubMed ID: 8223121
[TBL] [Abstract][Full Text] [Related]
22. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
[TBL] [Abstract][Full Text] [Related]
23. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
Ljung T; Bäck R; Hellström-Lindberg E
Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
[TBL] [Abstract][Full Text] [Related]
24. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
Cazzola M
Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
[TBL] [Abstract][Full Text] [Related]
25. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
Spiriti MA; Latagliata R; Niscola P; Cortelezzi A; Francesconi M; Ferrari D; Volpe E; Clavio M; Grossi A; Reyes MT; Musto P; Mitra ME; Azzarà A; Pagnini D; D'Arena G; Spadano A; Balleari E; Pecorari P; Capochiani E; De Biasi E; Perego D; Monarca B; Pisani F; Scaramella G; Petti MC
Ann Hematol; 2005 Mar; 84(3):167-76. PubMed ID: 15592833
[TBL] [Abstract][Full Text] [Related]
26. Long-term erythropoietin therapy improves response in myelodysplastic syndrome.
Ohshima M; Ubara Y; Tagami T; Sawa N; Suwabe T; Yamakawa K; Hoshino J; Katori H; Takemoto F; Hara S; Miyakoshi J; Takaichi K
Ther Apher Dial; 2005 Aug; 9(4):362-6. PubMed ID: 16076383
[TBL] [Abstract][Full Text] [Related]
27. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
Musto P; Falcone A; Sanpaolo G; Bodenizza C
Leuk Res; 2006 Apr; 30(4):385-8. PubMed ID: 16219350
[TBL] [Abstract][Full Text] [Related]
28. Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome.
Arboscello E; Botta M; Lerza R; Bogliolo G; Clavio M; Miglino M; Mencoboni M; Pannacciulli I
Anticancer Res; 2002; 22(3):1819-24. PubMed ID: 12168875
[TBL] [Abstract][Full Text] [Related]
29. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
Castelli R; Deliliers GL; Colombo R; Moreo G; Gallipoli P; Pantaleo G
Ann Hematol; 2014 Sep; 93(9):1523-9. PubMed ID: 24711171
[TBL] [Abstract][Full Text] [Related]
30. [Short-term curative effect of amifostine combined with rhbeta-EPO on patients with pure erythroid aplasia].
Li SX; Zhu HL; Lu XC; Fan H; Guo B; Zhai B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1103-6. PubMed ID: 18928605
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
[TBL] [Abstract][Full Text] [Related]
32. Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports.
Valent P
Leuk Res; 2008 Sep; 32(9):1333-7. PubMed ID: 18417212
[TBL] [Abstract][Full Text] [Related]
33. Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome.
Yilmaz A; Kaufmann CC; Binder C; Wörmann B; Haase D
Ann Hematol; 2001 Jan; 80(1):53-7. PubMed ID: 11233778
[TBL] [Abstract][Full Text] [Related]
34. Changes in hemopoietic precursors after treatment of low-risk myelodysplasia with amifostine.
Ribeiro E; Lima CS; Metze K; Souza CA; Lorand-Metze I
In Vivo; 2003; 17(2):181-4. PubMed ID: 12792983
[TBL] [Abstract][Full Text] [Related]
35. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?
Clavio M; Balleari E; Garrone A; Ballerini F; Varaldo R; Michelis GL; Balocco M; Abdall N; Colombo N; Grasso R; Gobbi M
J Exp Clin Cancer Res; 2005 Mar; 24(1):5-16. PubMed ID: 15943026
[TBL] [Abstract][Full Text] [Related]
36. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
[TBL] [Abstract][Full Text] [Related]
37. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Suwanawiboon B; Sumida KN
Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
Marsh JC; Ganser A; Stadler M
Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
[TBL] [Abstract][Full Text] [Related]
40. Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.
Schanz J; Jung H; Wörmann B; Gassmann W; Petersen T; Hinke A; Haase D
Leuk Res; 2009 Sep; 33(9):1183-8. PubMed ID: 19411105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
